F. No: 7-5/2016/EU/WC-362 Government of India Directorate General of Health Services Central Drugs Standard Control Organization (International Cell)

FDA Bhawan, Kotla Road, New Delhi- 110 002. Dated: 0 6 MAY 2019

То

M/s Honour Lab Limited, Unit-III,Plot No.4,Hetero infrastructure Ltd., SEZ,N.Narsapur(V),Nakkapally(M),Visakhapatnam, Andhra Pradesh -531081,INDIA.

Sub: Written Confirmation of M/s Honour Lab Limited, Unit-III, Plot No.4,Hetero infrastructure Ltd. SEZ, N.Narsapur(V), Nakkapally(M),Visakhapatnam, Andhra Pradesh - 531081 INDIA of as per requirement of EU for import of active substances imported into theEuropean Union (EU) for medicinal products for human use, in accordance with Article 46b (2) (b) of Directive 2001/83/EC from India-Reg.

Sir,

Please refer to your application submitted to CDSCO, Hyderabad Zonal office and the recommendation received from DDC (I), Hyderabad Zone on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

- 1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
- 2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.
- 3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
- 4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.
- 5. The Written Confirmation will be withdrawn in the event of non-compliance of Standards.
- 6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.

- 7. In the event of any Non Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
- 8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of issue	Valid up to
01	05	0 6 MAY 2019	Three years from date of issue
02	06	06 MAY 2019	Three years from date of issue

Yours faithfully,

(Dr.S.Eswara Reddy) Drugs Controller General (India).



\$ 30-04-19 Mr. AlloSII



御 御 御 御

GOVERNMENT OF INDIA MINISTRY OF HEALTH & FAMILY WELFARE Central Drugs Standard Control Organization

CERTIFICATE NO. :

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site:M/s Honour Lab Limited, Unit-III,Plot No.4, Hetero infrastructure Ltd., SEZ,N.Narsapur(V), Nakkapally(M),Visakhapatnam, Andhra Pradesh -531081.

2. Manufacturer's license number: 26/VP/AP/2013/B/G dt: 30.08.2013

Regarding the manufacturing plant under (1) of the following Active substance(s) exported to the EU for medicinal products for human use

As per List enclosed as Annexure- 01&02

The issuing Regulatory Authority hereby confirms that:

The standards of good manufacturing practice applicable to this manufacturing plant are at least equivalent to those laid down in the EU(= GMP of WHO/ICH Q7),

The manufacturing plant is subject to regular, strict and transparent controls and to the effective enforcement of good manufacturing practice, including repeated and unannounced inspections, so as to ensure a protection of public health at least equivalent to that in the EU; and

In the event of findings relating to non-compliance, information on such findings is supplied by the exporting third country without delay to the EU.

Date of Inspection of the plant: 23rd & 24th Jan 2019

The Written Confirmation remains valid until: Three years from the date of issue

The authenticity of this written confirmation may be verified with the issuing regulatory authority.

This written confirmation is without prejudice to the responsibilities of the manufacturer to ensure the quality of the medicinal product in accordance with Directive 2001/83/EC.

Address of the issuing regulatory authority: Central Drugs Standard Control Organisation FDA Bhawan, Kotla Road,

New Delhi- 110 002,india.

Name and function of responsible person:

Dr. S. Eswara Reddy. Drugs Controller General (India).

E-mail: Telephone no.: Fax no.:

Signature

30.04.10

<u>dci@nic.ın,</u> +91-11-23236965 +91-11-23236973

Stamp of the authority and date



GOVERNMENT OF INDIA MINISTRY OF HEALTH & FAMILY WELFARE Central Drugs Standard Control Organization

MARCHAR MARCHAR

Annexure- 01 WC 362

CERTIFICATE NO. :

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s Honour Lab Limited, Unit-III,Plot No.4, Hetero infrastructure Ltd., SEZ,N.Narsapur(V), Nakkapally(M),Visakhapatnam, Andhra Pradesh -531081.

List of APIs:

S. No.	Active substance (s)	Activity(ies)
1	Dapagliflozin (Amorphous) IH	Manufacturing & Packing
2	Empagliflozin IH	Manufacturing & Packing
3.	Empagliflozin (Amorphous) IH	Manufacturing & Packing
4.	Sitagliptin Phosphate Anhydrous IH	Manufacturing & Packing
5.	Pirfenidone Ph.Eur	Manufacturing & Packing
		101

ITEM(S) Five (05) Only

The Written Confirmation remains valid until: (03) Three years from the date of issue

Signature

Stamp of the authority and date

0 6 MAY 2019

0k

GOVERNMENT OF INDIA MINISTRY OF HEALTH & FAMILY WELFARE Central Drugs Standard Control Organization

Annexure- 02 CERTIFICATE NO. : WC 362

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s Honour Lab Limited,

Unit-III, Plot No.4,Hetero infrastructure Ltd., SEZ,N.Narsapur(V), Nakkapally(M),Visakhapatnam, Andhra Pradesh -531081.

List of APIs:

S. No.	Active substance (s)	Activity(ies)
1	Macitentan IH	Manufacturing & Packing
2.	Edoxaban Tosylate Monohydrate IH	Manufacturing & Packing
3.	Brexpiprazole IH	Manufacturing & Packing
4	Tavaborole IH	Manufacturing & Packing
5.	Sacubitril Valsartan Sodium Hydrate IH	Manufacturing & Packing
and the second se	Posaconazole (Form-I) IH	Manufacturing & Packing
	ITEM(S) SIX (06) C	Dnly

This certificate is being issued subject to condition that the firm shall obtain NOC from the Competent Authority, on case to case basis, to manufacture the above mentioned active substances for the purpose of export only, as the above mentioned active substances are not approved for manufacture or sale in India

The Written Confirmation remains valid until: (03) Three years from the date of issue

Signature

Stamp of the authority and date

0 6 MAY 2019